Patients on vitamin K treatment: is switching to direct-acting oral anticoagulation cost-effective? A target trial on a prospective cohort.

Helena AebersoldFabienne Foster-WitassekStefanie AeschbacherJuerg H BeerEva BlozikManuel BlumLeo BonatiGiulio ConteMichael CoslovskyMaria Luisa De PernaMarcello Di ValentinoStefan FelderCarola A HuberGiorgio MoschovitisAndreas MuellerRebecca E PaladiniTobias ReichlinNicolas RodondiAnnina StauberChristian SticherlingThomas D SzucsDavid ConenMichael KuhneStefan OsswaldMatthias SchwenkglenksMiquel Serra-Burrielnull null

Published in: Open heart (2024)

Applying a causal inference method to real-world data, we could not demonstrate switching to DOACs to be cost-effective for AF patients with at least 1 year of VKA treatment. Our estimates align with results from a previous randomised trial.

Keyphrases

atrial fibrillation
end stage renal disease
study protocol
newly diagnosed
ejection fraction
chronic kidney disease
combination therapy
single cell
machine learning
electronic health record
prognostic factors
open label
patient reported outcomes
double blind
placebo controlled